PE20060318A1 - Forma de administracion para la contracepcion hormonal - Google Patents
Forma de administracion para la contracepcion hormonalInfo
- Publication number
- PE20060318A1 PE20060318A1 PE2005000594A PE2005000594A PE20060318A1 PE 20060318 A1 PE20060318 A1 PE 20060318A1 PE 2005000594 A PE2005000594 A PE 2005000594A PE 2005000594 A PE2005000594 A PE 2005000594A PE 20060318 A1 PE20060318 A1 PE 20060318A1
- Authority
- PE
- Peru
- Prior art keywords
- folic acid
- administration
- daily
- hormone
- units
- Prior art date
Links
- 230000003054 hormonal effect Effects 0.000 title 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 8
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 abstract 4
- 229960000304 folic acid Drugs 0.000 abstract 4
- 235000019152 folic acid Nutrition 0.000 abstract 4
- 239000011724 folic acid Substances 0.000 abstract 4
- 229940088597 hormone Drugs 0.000 abstract 4
- 239000005556 hormone Substances 0.000 abstract 4
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 abstract 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 1
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 abstract 1
- 229960005309 estradiol Drugs 0.000 abstract 1
- 229930182833 estradiol Natural products 0.000 abstract 1
- 229960004766 estradiol valerate Drugs 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 abstract 1
- 229960004400 levonorgestrel Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 abstract 1
- 239000000583 progesterone congener Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
SE REFIERE A UNA FORMA DE ADMINISTRACION ORAL DIARIA ININTERRUMPIDA, QUE CONSISTE EN: A) AL MENOS 21 A 25 UNIDADES DIARIAS DE HORMONAS CARACTERIZADAS POR COMBINACION DE ESTROGENOS TALES COMO ESTRADIOL, VALERATO DE ESTRADIOL, MESTRANOL, ETINILESTADIOL; GESTAGENO SELECCIONADO DE NORGESTREL, GESTODEN, NORETISTERONA, NORGESTIMAT, ENTRE OTROS; Y ACIDO FOLICO ENTRE 5-200 ug; B) 7 A 3 UNIDADES DIARIAS DE UNA CANTIDAD MAYOR DE 200 ug DE ACIDO FOLICO, HASTA LA CANTIDAD MAXIMA ADMITIDA PARA MUJERES. DICHA FORMA DE ADMINISTRACION PERMITE EQUIPAR CON ACIDO FOLICO LA FORMULACION, TOMANDO EN CUENTA LOS DIFERENTES REQUERIMIENTOS DE ACIDO FOLICO DURANTE EL CICLO DE ADMINISTRACION DE HORMONAS Y DURANTE UNA TOMA POSTRIOR DE UNIDADES DIARIAS QUE NO CONTIENEN HORMONAS, SIENDO UTILES EN LA ANTICONCEPCION HORMONAL
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004026671A DE102004026671A1 (de) | 2004-05-28 | 2004-05-28 | Darreichungsform zur hormonalen Kontrazeption |
| DE102004026670A DE102004026670A1 (de) | 2004-05-28 | 2004-05-28 | Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20060318A1 true PE20060318A1 (es) | 2006-06-15 |
Family
ID=34969970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005000594A PE20060318A1 (es) | 2004-05-28 | 2005-05-27 | Forma de administracion para la contracepcion hormonal |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP2263659A1 (es) |
| AR (1) | AR049065A1 (es) |
| DK (1) | DK1755562T3 (es) |
| ES (1) | ES2438734T3 (es) |
| PE (1) | PE20060318A1 (es) |
| PL (1) | PL1755562T3 (es) |
| PT (1) | PT1755562E (es) |
| SI (1) | SI1755562T1 (es) |
| WO (1) | WO2005115349A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005053771A1 (de) | 2005-11-09 | 2007-05-10 | Grünenthal GmbH | Darreichform zur hormonalen Kontrazeption |
| DE112007001600A5 (de) * | 2006-07-06 | 2009-04-30 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen |
| EP1891959A1 (de) * | 2006-08-14 | 2008-02-27 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| PL3106148T3 (pl) | 2015-06-18 | 2018-08-31 | Mithra Pharmaceuticals S A | Jednostka dawkowania ulegająca rozpadowi w jamie ustnej zawierająca składnik estetrolowy |
| CN107810001A (zh) | 2015-06-18 | 2018-03-16 | 密特拉制药公司 | 含雌四醇的口腔分散片剂 |
| CA2988362C (en) | 2015-06-18 | 2022-07-19 | Mithra Pharmaceuticals S.A. | Orodispersible tablet containing estetrol |
| CN107787224A (zh) | 2015-06-18 | 2018-03-09 | 密特拉制药公司 | 含雌四醇组分的口腔分散剂量单位 |
| CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
| JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| TWI893101B (zh) | 2020-04-16 | 2025-08-11 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB888631A (en) * | 1959-02-24 | 1962-01-31 | Upjohn Co | Improvements in or relating to oral therapeutic compositions comprising steroids |
| AU3567699A (en) | 1998-04-17 | 1999-11-08 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Folic acid-containing pharmaceutical compositions, and related methods and delivery systems |
| US6911438B2 (en) * | 2001-09-12 | 2005-06-28 | Jonathan V. Wright | Hormone replacement formulation |
-
2005
- 2005-05-27 PL PL05750712T patent/PL1755562T3/pl unknown
- 2005-05-27 EP EP10008750A patent/EP2263659A1/de not_active Withdrawn
- 2005-05-27 PT PT57507121T patent/PT1755562E/pt unknown
- 2005-05-27 SI SI200531805T patent/SI1755562T1/sl unknown
- 2005-05-27 EP EP05750712.1A patent/EP1755562B1/de not_active Expired - Lifetime
- 2005-05-27 DK DK05750712.1T patent/DK1755562T3/da active
- 2005-05-27 AR ARP050102210A patent/AR049065A1/es unknown
- 2005-05-27 PE PE2005000594A patent/PE20060318A1/es not_active Application Discontinuation
- 2005-05-27 ES ES05750712.1T patent/ES2438734T3/es not_active Expired - Lifetime
- 2005-05-27 WO PCT/EP2005/005761 patent/WO2005115349A1/de not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| PT1755562E (pt) | 2013-12-26 |
| AR049065A1 (es) | 2006-06-21 |
| ES2438734T3 (es) | 2014-01-20 |
| EP1755562B1 (de) | 2013-10-09 |
| SI1755562T1 (sl) | 2014-02-28 |
| DK1755562T3 (da) | 2013-12-16 |
| EP1755562A1 (de) | 2007-02-28 |
| EP2263659A1 (de) | 2010-12-22 |
| WO2005115349A1 (de) | 2005-12-08 |
| PL1755562T3 (pl) | 2014-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2561810T3 (es) | Antagonistas de progesterona tales como CDB-4124 para reducir el dolor asociado a endometriosis y fibroides uterinos | |
| PE20060318A1 (es) | Forma de administracion para la contracepcion hormonal | |
| EP2512486B1 (en) | Nestorone®/estradiol transdermal gel | |
| CR10732A (es) | Uso de valerato de estradiol o 17 b- estradiol en combinacion con dienogest en una terapia oral para mantener y / o incrementar la libido femenina | |
| JP2013018787A5 (es) | ||
| CR7022A (es) | Productos esteroides hormonales y metodos para su preparacion | |
| MEP38008A (en) | Drospirenone for hormone replacement therapy | |
| CR7420A (es) | Composiciones farmaceuticas que comprenden uno o varios esteroides, uno o varios componentes de tetrahiidrofolatos y vitamina b12 | |
| BR112014031910A2 (pt) | formulações e terapias naturais de combinação para reposição hormonal | |
| BR112014031914A2 (pt) | cápsula de estradiol solúvel para inserção vaginal | |
| BR0313921A (pt) | Regime de reposição de estrogênio | |
| CR7611A (es) | Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona | |
| CR9626A (es) | Formas de dosificacion de liberacion retardada oral altamente biodisponible de un o-desmetilvenlafaxin succinato | |
| AR048722A1 (es) | Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos | |
| WO2004091630A8 (ja) | 眼に適用する疾患治療剤 | |
| AR061959A1 (es) | Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas | |
| PE20061415A1 (es) | Composicion farmaceutica que contiene gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato | |
| PE20070188A1 (es) | Formulaciones de estrogenos conjugados y bazedoxifeno | |
| CL2015003014A1 (es) | Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas. | |
| MX2009013305A (es) | Composicion farmaceutica de un nuevo sistema para liberacion vaginal de esteroides. | |
| PA8789401A1 (es) | Estratrienos 8-beta-sustituidos como estrógenos de acción selectiva | |
| UA108865C2 (uk) | Парентеральна фармацевтична композиція у вигляді суспензії уповільненого вивільнення, у низькій та наднизькій дозованій формі, у гормональній терапії при клімактеричному синдромі | |
| WO2008144355A3 (en) | Stable, self-microemulsifying fenofibrate compositions | |
| EP3747443A3 (en) | Use of an oestrogen in the manufacture of a composition containing oestrogen for the treatment of atrophic vaginitis | |
| AR062323A1 (es) | Forma farmacologica peroral para la anticoncepcion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |